Skip to main content

Novo Nordisk A/S ADR(NVO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low38.70
Day High40.20
Open:40.13
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program
Tipranks
Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme
Tipranks
J.P. Morgan Sticks to Its Hold Rating for Novo Nordisk (0QIU)
Tipranks
Novo Nordisk (0QIU) Receives a Hold from Jefferies
Motley Fool
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly
Tipranks
Novo Nordisk’s Etavopivat Hits Phase 3 Goals in Sickle Cell Disease, Regulatory Filing Planned for Late 2026
Motley Fool
Here's Why Agios Pharmaceuticals Crashed 23% Today
Motley Fool
This Drug Stock Has Crushed the S&P 500 Over the Last Decade
Tipranks
Novo Nordisk Maps Heart Risk in New Diabetes Patients Across Southeast Asia
MarketBeat
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
MarketBeat.com
Motley Fool
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?
Motley Fool
Should You Forget CVS Health and Invest in a Purer Healthcare Play?
Motley Fool
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market
Tipranks
Novo Nordisk (0QIU) Receives a Hold from Jefferies
Motley Fool
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
Motley Fool
Could AbbVie Crash Lilly's Weight‑Loss Party?
Tipranks
Novo Nordisk Advances DKK 15 Billion Share Buyback, Holds 0.6% in Treasury Stock as of 10 April 2026
Tipranks
Novo Nordisk’s EVOKE Alzheimer’s Trial: What the Latest Update Means for NVO Investors
Tipranks
UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)
Motley Fool
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker?
Motley Fool
3 Absurdly Cheap Dividend Stocks to Buy in April 2026
Tipranks
Novo Nordisk Updates Progress on 2026 DKK 15 Billion Share Buyback
MarketBeat
Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?
MarketBeat.com
Motley Fool
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
Motley Fool
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Imunon (IMNN) and Novo Nordisk (NVO)
Motley Fool
Why Eli Lilly Stock Trounced the Market Today
Motley Fool
Could This New Approval Be a Turning Point For Novo Nordisk?
Zacks Investment Research
PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play
PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play
Motley Fool
Is This Weight Loss Drug Stock a Buy After a New Approval?
Tipranks
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme
Tipranks
Barclays Remains a Hold on Novo Nordisk (0QIU)

Profile

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.